Get the Stockscreener App
1.40
6.06%
0.08
Heron Therapeutics Inc stock is traded at $1.40, with a volume of 3.51M.
It is up +6.06% in the last 24 hours and down -26.32% over the past month.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
See More
Previous Close:
$1.32
Open:
$1.33
24h Volume:
3.51M
Relative Volume:
2.31
Market Cap:
$214.61M
Revenue:
$137.74M
Net Income/Loss:
$-27.97M
P/E Ratio:
-8.75
EPS:
-0.16
Net Cash Flow:
$-9.61M
1W Performance:
+5.26%
1M Performance:
-26.32%
6M Performance:
-19.08%
1Y Performance:
-25.13%
1-Day Range:
$1.33
$1.4195
1-Week Range:
$1.25
$1.4195
52-Week Range:
$1.04
$2.68
Heron Therapeutics Inc Stock (HRTX) Company Profile
Name
Heron Therapeutics Inc
Sector
Industry
Phone
(858) 251-4400
Address
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
1.40 | 199.28M | 137.74M | -27.97M | -9.61M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Initiated | H.C. Wainwright | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-24 | Initiated | CapitalOne | Overweight |
| Mar-13-24 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Buy |
| Feb-20-20 | Reiterated | Needham | Buy |
| Jan-16-19 | Reiterated | Needham | Buy |
| Apr-05-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Mar-01-18 | Reiterated | Needham | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Outperform |
| Sep-27-17 | Initiated | Northland Capital | Outperform |
| Feb-27-17 | Initiated | Needham | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| May-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Dec-10-15 | Initiated | Lake Street | Buy |
| Sep-23-15 | Reiterated | Leerink Partners | Outperform |
| Sep-02-15 | Initiated | BofA/Merrill | Buy |
| Aug-03-15 | Reiterated | Brean Capital | Buy |
| Jun-30-15 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-19-15 | Reiterated | Leerink Partners | Outperform |
| Aug-07-14 | Initiated | Noble Financial | Buy |
View All
Heron Therapeutics Inc Stock (HRTX) Latest News
Sector Rotation Brings Heron Therapeutics Inc. Into Focus2025 Winners & Losers & Accurate Entry/Exit Alerts - newsyoung.net
Technical Models Detect Momentum Build in Heron Therapeutics Inc.Weekly Trade Review & Fast Gain Swing Trade Alerts - classian.co.kr
Heron Therapeutics Inc. Stages Intraday Comeback — Trend Change2025 AllTime Highs & Trade Opportunity Analysis Reports - newsyoung.net
Heron Therapeutics (NASDAQ:HRTX) Stock Rating Upgraded by Zacks Research - MarketBeat
Heron Therapeutics Inc. Facing Inflection Point in Trend AnalysisJuly 2025 Patterns & Smart Investment Allocation Tips - newsyoung.net
Can Traders Expect Breakout From Heron Therapeutics Inc. This WeekJuly 2025 Chart Watch & Expert Approved Momentum Ideas - 선데이타임즈
XTX Topco Ltd Sells 213,080 Shares of Heron Therapeutics, Inc. $HRTX - MarketBeat
Adam Morgan Acquires 1,766,546 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock - MarketBeat
Heron Therapeutics Adopts Tax Benefit Preservation Plan - MSN
Informed Momentum Co LLC Takes $768,000 Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Tick level data insight on Heron Therapeutics Inc. volatilityMarket Growth Report & Technical Entry and Exit Alerts - Newser
Will Heron Therapeutics Inc. outperform the marketJuly 2025 PostEarnings & Weekly Market Pulse Alerts - Newser
Heron Therapeutics, Inc. (NASDAQ:HRTX) Major Shareholder Rubric Capital Management Lp Buys 2,387,225 Shares - MarketBeat
Heron Therapeutics Inc. stock trendline breakdownJuly 2025 Fed Impact & Consistent Profit Focused Trading Strategies - Newser
How to build a dashboard for Heron Therapeutics Inc. stockTrade Analysis Summary & Community Verified Swing Trade Signals - Newser
Is Heron Therapeutics Inc. undervalued by DCF analysisRecession Risk & Entry Point Confirmation Signals - newsyoung.net
Using portfolio simulators with Heron Therapeutics Inc. includedJuly 2025 Recap & Weekly Market Pulse Alerts - Newser
Heron Therapeutics Inc. stock volume spike explainedJuly 2025 Big Picture & AI Based Buy/Sell Signal Reports - Newser
Technical analysis overview for Heron Therapeutics Inc. stockPortfolio Value Report & Verified Chart Pattern Signals - Newser
Custom strategy builders for tracking Heron Therapeutics Inc.Quarterly Trade Summary & Long-Term Safe Return Strategies - Newser
Strategic Tax Preservation as a Catalyst for Long-Term Value Creation: Heron Therapeutics' Section 382 Rights Plan and Its Implications for Biotech Investors - AInvest
Heron Therapeutics Adopts Rights Plan to Protect Tax Benefits - MarketScreener
Heron Therapeutics adopts tax benefits preservation plan - TipRanks
Strategic Tax Planning as a Catalyst for Shareholder Value: Heron Therapeutics' Section 382 Rights Plan - AInvest
Heron Therapeutics adopts tax benefits plan to protect $1.37 billion in NOLs - Investing.com
$1.37 Billion Tax Asset Protection: Heron Therapeutics Adopts Strategic Rights Plan to Preserve NOLs - Stock Titan
Will Heron Therapeutics Inc. face regulatory challengesJuly 2025 Intraday Action & Safe Capital Investment Plans - newsyoung.net
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2025 Earnings Call Transcript - MSN
Heron Therapeutics (NASDAQ:HRTX) Announces Quarterly Earnings Results - MarketBeat
DLA Piper advises Heron Therapeutics in comprehensive capital financings - DLA Piper
Heron Therapeutics Signs Agreement with Patheon - MSN
Heron Therapeutics’ Earnings Call Highlights Growth and Strategy - TipRanks
Published on: 2025-08-14 05:28:34 - Newser
XTX Topco Ltd Sells 213,080 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Needham & Company LLC Cuts Heron Therapeutics (NASDAQ:HRTX) Price Target to $3.00 - MarketBeat
Heron Therapeutics Strengthens Financial Position with Refinancing - MSN
Heron Therapeutics (NASDAQ:HRTX) Lowered to Hold Rating by Wall Street Zen - MarketBeat
Warner Bros Discovery Director Buys $3.55M Worth of WBD Shares, Heron Therapeutics Director Purchases $2.65M Worth of HRTX Shares - AInvest
Heron Therapeutics Soars 13.74% on Insider Buying, Strategic Moves - AInvest
Rubric Capital and Director Morgan Make Significant Investments in Heron Therapeutics - AInvest
Heron Therapeutics Strengthens Financial Position with Refinancing and Board Changes - AInvest
Heron Therapeutics Inc Stock (HRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Heron Therapeutics Inc Stock (HRTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morgan Adam | Director |
Aug 08 '25 |
Buy |
1.50 |
1,766,546 |
2,649,819 |
8,753,290 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):